I do not belive so. First, Cytodyn had a deal wit
Post# of 148104
First, Cytodyn had a deal with AMAREX and not Nader with Kazam.
Might be that Nader pushed Kaz to speed up and to file a not finished BLA but this has nothing to do with all the other shortcommings. Like the flawed AMAREX data which makes it impossible to file a proper HIV BLA (testified by three other CROs) with this trial data ever again or missing safety data, botched trial designs and many other things we are still not aware of.
Cytodyn spend many years and lots of $ for the HIV trial and everything is now worthless due to AMAREX shortcommings over all those years. This and the lost potential revenue are the real damages in my opinion and AMAREX will pay.